Treatment with HMGB1 antagonists was successful in preclinical models of many diseases including sepsis, arthritis or autoimmune carditis.106 Clinically only ethyl pyruvate has been tested in a trial with patients undergoing cardiac surgery, where it was generally well tolerated although it did not improve outcomes.107. This evidence concerns the gene HMGB1 and Arthritis.